Heart failure & cardiomyopathiesResearch article
Right Ventricular Metrics as End Points in Clinical Trials
- Narrative review
Authors' conclusion
RV-specific end points hold substantial promise for enhancing the sensitivity and mechanistic insight of clinical trials but remain inadequately integrated into current practice.
Study context
- Population
- Patients in interventional cardiovascular clinical trials (HF, cardiomyopathies, valve diseases, pulmonary hypertension, congenital heart conditions)
Main finding
As reported in the abstract
Role of RV-focused imaging and haemodynamic parameters as clinical trial end points
- Right ventricular (RV) parameters from echocardiography, CMR, CT and right heart catheterization show potential value in assessing therapeutic effects across HF, cardiomyopathies, valve diseases, pulmonary hypertension and congenital heart conditions
- Use inconsistent; feasibility challenges common, particularly in multicentre trials
- Key limitations: variability in imaging acquisition, incomplete data capture, lack of standardized protocols, insufficient validation linking short-term RV changes to long-term outcomes
- Emerging tools such as artificial intelligence may improve reproducibility and efficiency
Original publication
Right Ventricular Metrics as End Points in Clinical Trials. JAMA Cardiol. Published 1 August 2026. doi:10.1001/jamacardio.2026.2053
Summarised from the published abstract; every number is checked against it